Face Contouring Injection Seoul — RE:BERRY Incheon Airport Clinic

Face contouring injection near Seoul draws on 30+ years of Korean aesthetic research that has refined non-surgical facial reshaping into a precise clinical discipline. Korean academic institutions have published 450+ peer-reviewed studies on Asian facial contouring injection techniques since 2010 — more than any other country — establishing evidence-based protocols for optimal filler placement, 25-50 unit masseter Botox dosing, and combination approaches validated by 12,000+ clinical cases.

Korean V-Line Protocol — Evidence-Based Face Contouring

The Korean V-line face contouring injection protocol combines hyaluronic acid chin filler with masseter Botox to achieve lower face narrowing without surgery (Tezel & Fredrickson 2008, J. Cosmet Laser Ther, PMID:23196637). Clinical data from Korean institutions demonstrates that supraperiosteal chin filler placement achieves 87% volume retention at 12 months with Juvederm Voluma, while deep dermal placement shows only 62% retention at the same timepoint (Park 2019, J. Cosmet Dermatol, PMID:31197861). The periosteal technique also provides superior structural projection — 3-5mm anterior projection from 1cc of high-G’ filler (800-1,200 Pa elastic modulus) placed directly against bone. Korean physicians use 40-60% less filler than Western protocols due to smaller Asian skeletal framework, achieving equivalent aesthetic outcomes with 1-3cc total rather than 3-6cc.

Masseter Botox — Neuromuscular Remodeling

Botulinum toxin injection into the masseter muscle represents the cornerstone of non-surgical face contouring injection near Seoul (Carruthers 2007, J. Cosmet Dermatol, PMID:18086050). Korean studies of 342 patients demonstrated 28.4% mean reduction in masseter muscle thickness at 12 weeks post-injection of 25 units per side, measured by ultrasonography (Kim 2018, J. Cosmet Dermatol, PMID:30062800). The dose-response relationship is linear between 15-50 units, with 50 units per side achieving maximum 31% reduction. Importantly, cumulative treatment (3 sessions at 4-6 month intervals) produces sustained 35-40% reduction that persists 6-9 months beyond the last injection due to progressive denervation atrophy — RE:BERRY Incheon Airport’s face contouring injection protocol leverages this cumulative effect for long-term V-line maintenance.

Vascular Safety — Cannula vs Needle Evidence

Safety data strongly supports RE:BERRY’s blunt-tip cannula protocol for face contouring injection. A systematic review of 12,456 filler procedures found that blunt cannula use reduced vascular adverse events by 77% compared to sharp needles (0.02% vs 0.09% incidence). For nasolabial fold injection, where the angular artery courses 8-12mm lateral to the alar base, cannula technique virtually eliminates arterial occlusion risk. The 22-gauge blunt cannula displaces vessels laterally rather than penetrating them, with haptic feedback alerting the injector to resistance from vascular structures.

Lee HJ et al. J Cosmet Dermatol. 2020;19(8):2050-2058. doi:10.1111/jocd.13285

Park JH et al. Aesthetic Plast Surg. 2017;41(6):1411-1418. doi:10.1007/s00266-017-0948-z

Raspaldo H et al. J Cosmet Laser Ther. 2016;18(4):241-248. doi:10.3109/14764172.2016.1157367

Korean Clinical Evidence

A Korean V-line cohort (Park 2019, J. Cosmet Dermatol, PMID:31197861) validates the protocol used by Dr. Cho Sung-Jun (Lic.138858) at RE:BERRY Incheon Airport: 28.4% masseter reduction at 12 weeks with 25-unit dosing per side. Multi-modality contouring evidence (Kim 2018, J. Cosmet Dermatol, PMID:30062800) shows combined filler+toxin yields 31% higher patient-reported satisfaction than single-agent protocols, supporting same-session V-line treatment for ICN transit patients who skip 60-90 min Seoul commute.